Yamaguchi Junji, Makino Kunihiko, Kusunose Yukiko, Higa Shirika, Takagi Takuro, Suzuki Ken, Lee Tetsuo
Division of Internal Medicine, Toshiba General Hospital, 6-3-22 Higashi-ohi, Shinagawa-ku, Tokyo 140-8522, Japan.
Division of Cardiovascular Medicine, Toshiba General Hospital, Tokyo, Japan.
J Cardiol Cases. 2013 Jun 7;8(2):e77-e80. doi: 10.1016/j.jccase.2013.05.002. eCollection 2013 Aug.
We report a case of deep venous thrombosis and pulmonary embolism treated with rivaroxaban due to warfarin allergy. The patient responded well to a low dose of 15 mg/day. There has been a report about treating patients with atrial fibrillation using a low dose of rivaroxaban in Japan, but no previous reports about deep vein thrombosis/pulmonary embolism. This case suggests that rivaroxaban could be an alternative to warfarin for the treatment of deep vein thrombosis and pulmonary embolism in Japanese patients with warfarin allergy. < Recently, several new anticoagulant medications have been released, but their efficacy has not been clarified. Rivaroxaban has shown efficacy for atrial fibrillation, deep vein thrombosis, and pulmonary embolism in Europe and the USA, but this has not been demonstrated in Japan. The present case suggests that rivaroxaban can improve deep vein thrombosis and pulmonary embolism in Japanese patients at a low dose.>.